Stalicla secures USD 17.4 million in Series B Funding for precision medicine in neuropsychiatric and neurological disorders

16.01.2024 14:50, Rita Longobardi

Stalicla, a clinical-stage biopharmaceutical company dedicated to advancing precision medicine solutions for neuropsychiatric and neurological disorders, has reached a significant achievement by successfully concluding the first phase of its Series B financing round. With the funds, the company signals strong support for its innovative pipelines to transform the landscape of treatment options for complex brain-related conditions.

The proceeds will be employed for the preparation of Stalicla’s precision Autism Spectrum Disorder (ASD) Phase II trial, the establishment of its platform, the launch of a Phase III study in Substance Use Disorders slated for 2025 — fully supported by the NIH /National Institute on Drug Abuse — and lastly, on the ramp-up of its ongoing patient identification trial currently enrolling in sites in the USA, Spain, and Australia. In addition, STALICLA has acquired global rights for Novartis’ drug candidate, mavoglurant, a treatment for substance-use disorders and neurodevelopmental disorders (NDDs), now called STP7.

To support these advancements, Stalicla will strengthen its Management Team and Board of Directors, reinforcing the foundation for the exciting journey ahead.

Led by SPRIM Global Investments, with key participation from core investors, this funding includes a USD 3.8 million credit facility.

“This financial backing underscores Stalicla's role as a trailblazer in the neuro-precision space with first applications in precision psychiatry. Additionally, our STP7 mGluR5 NAM platform is offering multifaceted advanced clinical development opportunities in the wider neurology space in a timely period of recent clinical progress and increased transaction activity level in the neurology and neuropsychiatry space," commented Lynn Durham, CEO of Stalicla. "There has never been a more promising time to advance transformative treatment options for millions of patients with brain diseases and Stalicla is determined to play a key role in this progress.”

Stalicla was ranked among the TOP 100 Swiss Startups in 2022.


Stalicla's team (from up left to down right): Eric Painbeni (Head of Clinical Operations), Laurent Forestier (CFO), Jean-Marc Hyvelin (Head of Operations), Lynn Durham (CEO and Founder), Atul Mahableshwarkar (Chief Medical Officer), Laura Perez-Cano (Head of Discovery), and Emre Guney (CTO)